Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
Source: View publication →
The PACIFIC-2 trial demonstrated that the addition of durvalumab to concurrent chemoradiotherapy (cCRT) followed by consolidation durvalumab did not result in a statistically significant improvement in progression-free survival compared to cCRT plus placebo in patients with unresectable stage III NSCLC.
Key Findings
Study Design
Study Limitations
Clinical Significance
The PACIFIC-2 study reinforces the standard of care for unresectable stage III NSCLC, which remains definitive concurrent chemoradiation followed by consolidation durvalumab (the PACIFIC regimen), rather than concurrent initiation of durvalumab with chemoradiation.
Historical Context
The original PACIFIC trial established sequential consolidation durvalumab as the global standard of care after definitive chemoradiation. PACIFIC-2 was initiated to explore if initiating immunotherapy earlier, during the chemoradiation phase, could further improve outcomes, particularly for patients who might not survive or complete the cCRT phase to receive later consolidation.
Guided Discussion
High-yield insights from every perspective
Explain the biological rationale behind combining ionizing radiation with immune checkpoint inhibitors like durvalumab in the treatment of non-small cell lung cancer.
Key Response
Radiation therapy induces immunogenic cell death, which leads to the release of tumor-associated antigens and damage-associated molecular patterns (DAMPs). This 'in situ vaccination' effect can enhance T-cell priming and recruitment, potentially overcoming the immunosuppressive tumor microenvironment and creating a synergistic effect when combined with PD-L1 inhibitors like durvalumab.
Given the results of the PACIFIC-2 trial, how should the timing of durvalumab initiation be managed for a patient with unresectable Stage III NSCLC who is currently undergoing concurrent chemoradiotherapy (cCRT)?
Key Response
The PACIFIC-2 trial failed to show a statistically significant improvement in progression-free survival (PFS) by starting durvalumab concurrently with cCRT. Therefore, clinicians should adhere to the established PACIFIC regimen, which initiates durvalumab as consolidation therapy only after the completion of cCRT, provided the patient has not progressed.
Analyze the potential role of radiation-induced lymphopenia as a contributing factor to the lack of efficacy observed in the concurrent durvalumab arm of PACIFIC-2.
Key Response
Concurrent chemoradiotherapy, particularly when involving large nodal volumes in Stage III NSCLC, often results in significant lymphopenia. Since durvalumab relies on functional circulating and intratumoral T-cells to exert its effect, the depletion of these lymphocytes during the concurrent phase may have neutralized the intended synergistic benefit of simultaneous immunotherapy and radiation.
How does the PACIFIC-2 data influence your clinical decision-making for patients who are unable to receive the full standard dose of radiation or chemotherapy—does the lack of benefit in the concurrent setting suggest a 'window of opportunity' was missed, or does it reinforce the necessity of the sequential approach?
Key Response
PACIFIC-2 reinforces the sequential approach (cCRT followed by IO). It suggests that the 'window' is not during active cytotoxic treatment, but rather in the post-treatment inflammatory phase. For patients who struggle with cCRT, the priority remains finishing the definitive local therapy safely to reach the consolidation phase, rather than trying to intensify the concurrent phase with immunotherapy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
From a trial design perspective, discuss how the inclusion of patients who progressed during the concurrent phase of PACIFIC-2 might have confounded the comparison against the historical PACIFIC trial cohort.
Key Response
In the original PACIFIC trial, patients were only randomized if they had *not* progressed after cCRT, effectively selecting a 'favorable-risk' population. PACIFIC-2 randomized patients at the start of cCRT, including those who would have progressed early or died during cCRT. This difference in 'time-zero' for randomization makes cross-trial comparisons difficult and may have diluted the perceived efficacy of the durvalumab arm due to early dropouts and disease biology.
As a reviewer, what critical concerns would you raise regarding the higher incidence of Grade 3/4 adverse events and treatment discontinuation in the experimental arm of PACIFIC-2, and how does this impact the study's primary endpoint analysis?
Key Response
The increased toxicity and higher discontinuation rates in the concurrent durvalumab arm (often due to pneumonitis or infection) suggest a lack of tolerability that could lead to informative censoring. If patients stop treatment early due to toxicity, they may not receive the full benefit of the consolidation phase, thereby biasing the PFS results toward the null and questioning the safety profile of simultaneous delivery.
Based on the PACIFIC-2 findings, should current NCCN or ASCO guidelines for Stage III NSCLC be amended to include concurrent durvalumab for specific subgroups, or does this study solidify consolidation-only therapy as the sole standard of care?
Key Response
Current guidelines (e.g., NCCN Category 1 for consolidation durvalumab) should remain unchanged. PACIFIC-2 failed its primary endpoint of PFS, and no specific subgroup demonstrated a compelling benefit that would warrant a change in practice. The evidence reinforces that concurrent immunotherapy with platinum-based chemoradiotherapy should not be used outside of a clinical trial.
Clinical Landscape
Noteworthy Related Trials
RTOG 0617
Tested
High-dose (74 Gy) vs standard-dose (60 Gy) radiotherapy with concurrent chemotherapy
Population
Unresectable Stage III NSCLC
Comparator
Standard-dose (60 Gy) radiotherapy
Endpoint
Overall survival
PACIFIC Trial
Tested
Durvalumab consolidation after chemoradiotherapy
Population
Unresectable Stage III NSCLC
Comparator
Placebo
Endpoint
Progression-free survival and overall survival
KEYNOTE-799
Tested
Pembrolizumab with concurrent chemoradiotherapy
Population
Unresectable Stage III NSCLC
Comparator
No direct comparator (single-arm phase II)
Endpoint
Objective response rate
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis